Published in Blood Weekly, May 23rd, 2002
As a developmental stage company, Northfield has no revenues.
For the third quarter, Northfield reported a loss of $2.6 million, or $0.18 cents per basic share compared with a loss of $2.6 million, or $0.18 cents per basic share, in the year earlier period. For the latest 9 months, net loss was $7.9 million, or $0.56 cents per basic share compared with a loss of $7.4 million, or $0.52 cents per basic share, in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.